African American Participation in Oncology Clinical Trials - Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions

Clinical Genitourinary Cancer

Volumn 14, Issue 2, 2016, Pages 105-116

  Ahaghotu, Chiledum ^a   Tyler, Robert ^b   Sartor, Oliver ^c  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Dendreon   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ethnicity; Racial disparities; Recruitment; Sociocultural elements; Underrepresentation

Indexed keywords

ABIRATERONE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; IPILIMUMAB; LENALIDOMIDE; ORTERONEL; RADIUM CHLORIDE RA 223; SATRAPLATIN; SIPULEUCEL T;

AFRICAN AMERICAN; AWARENESS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RESEARCH; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMMUNICATION SKILL; CULTURAL FACTOR; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE SYSTEM; HEALTH EDUCATION; HUMAN; LUNG CANCER; ONCOLOGY; PATIENT PARTICIPATION; PHYSICIAN; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SOCIAL STATUS; AGE; ETHNOLOGY; HEALTH EQUITY; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; TRENDS;

AFRICAN AMERICANS; AGE FACTORS; CLINICAL TRIALS AS TOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH EQUITY; HUMANS; MALE; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS;

EID: 84960439580     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.12.003     Document Type: Review

References (120)

1. K.S. Albain, J.M. Unger, J.J. Crowley, C.A. Coltman Jr., and D.L. Hershman Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group J Natl Cancer Inst 101 2009 984 992
2. SEER Database. Available at: http://seer.cancer.gov/faststats/selections.php?series=race. Accessed: August 20, 2015.
3. A.A. Aizer, T.J. Wilhite, M.H. Chen, and et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period Cancer 120 2014 1532 1539
4. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics CA Cancer J Clin 2015 2015 5 29
5. E. Goss, A.M. Lopez, C.L. Brown, D.S. Wollins, O.W. Brawley, and D. Raghavan American Society of Clinical Oncology policy statement: disparities in cancer care J Clin Oncol 27 2009 2881 2885
6. T. Gansler, M. Jin, J. Bauer, and et al. Outcomes of a cancer clinical trial matching service J Cancer Educ 27 2012 11 20
7. J.G. Ford, M.W. Howerton, G.Y. Lai, and et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review Cancer 112 2008 228 242
8. D.E. Spratt, and J.R. Osborne Disparities in castration-resistant prostate cancer trials J Clin Oncol 33 2015 1101 1103
9. L.A. Newman, C.T. Lee, L.P. Parekh, and et al. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients Cancer 106 2006 188 195
10. National Research Council The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved 1999 The National Academies Press Washington, DC
11. F.T. Shaya, and C.M. Gbarayor Huiwen Keri Yang, Agyeman-Duah M, Saunders E. A perspective on African American participation in clinical trials Contemp Clin Trials 28 2007 213 217
12. American Cancer Society. Cancer facts and figures 2015. Available at: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed: August 20, 2015.
13. American Cancer Society. Cancer facts & figures for African Americans 2013-2014. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036921.pdf. Accessed: August 20, 2015.
14. H. Williams, and I.J. Powell Epidemiology, pathology, and genetics of prostate cancer among African-Americans compared with other ethnicities Methods Mol Biol 472 2009 439 453
15. M.R. Cooperberg Re-examining racial disparities in prostate cancer outcomes J Clin Oncol 24 2013 2979 2980
16. I. Oakley-Girvan, L.N. Kolonel, R.P. Gallagher, A.H. Wu, A. Felberg, and A.S. Whittemore Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients Am J Public Health 93 2003 1753 1759
17. M.A. Hudson, S. Luo, T. Chrusciel, and et al. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans? Urol Oncol 32 2014 34.e9 34.e18
18. J.T. Bensen, Z. Xu, P.M. McKeigue, and et al. Admixture mapping of prostate cancer in African Americans participating in the North-Carolina-Louisiana Prostate Cancer Project (PCaP) Prostate 74 2014 1 9
19. S. Mandal, F. Abebe, and J. Chaudhary -174G/C polymorphism in the interleukin-6 promotor is differently associated with prostate cancer incidence depending on race Genet Mol Res 13 2014 139 151
20. J.D. Albano, E. Ward, A. Jemal, and et al. Cancer mortality in the United States by education level and race J Natl Cancer Inst 99 2007 1384 1394
21. A.G. Cuevas, L.R. Reitzel, C.E. Adams, and et al. Discrimination, affect, and cancer risk factors among African Americans Am J Health Behav 38 2014 31 41
22. W.R. Carpenter, P.A. Godley, J.A. Clark, and et al. Racial differences in trust and regular source of patient care and the implications for prostate cancer screening use Cancer 115 2009 5048 5059
23. V.L. Shavers, W. Underwood 3rd, and R.P. Moser Race/ethnicity, risk perception, and receipt of prostate-specific antigen testing J Natl Med Assoc 101 2009 698 704
24. K. Griffiths, M.S. Morton, and L. Denis Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer Eur Urol 35 1999 443 455
25. F.A. Ukoli, J.H. Fowke, P. Akumabor, and et al. The association of plasma fatty acids with prostate cancer risk in African Americans and Africans J Health Care Poor Underserved 21 1 Suppl 2010 127 147
26. A.A. Singh, L.W. Jones, J.A. Antonelli, and et al. Association between exercise and primary incidence of prostate cancer: does race matter? Cancer 119 2013 1338 1343
27. C.L. Bennett, M.R. Ferreira, T.C. Davis, and et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer J Clin Oncol 16 1998 3101 3104
28. D.B. Miller Pre-screening age African-American males: what do they know about prostate cancer screening, knowledge, and risk perceptions? Soc Work Health Care 53 2014 268 288
29. C. DeNavas-Walt, B.D. Proctor, and J.C. Smith US Census Bureau. Current Population Reports, P60-245, Income, Poverty, and Health Insurance Coverage in the United States 2012 US Government Printing Office Washington, DC 2012
30. U.N. Report 2008. Unequal Health Outcomes in the United States. Available at: http://www.prrac.org/pdf/CERDhealthEnvironmentReport.pdf. Accessed: March 25, 2015.
31. E. Onukwugha, P. Osteen, J. Jayasekera, C.D. Mullins, C.A. Mair, and A. Hussain Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors Cancer 120 2014 3385 3392
32. S.B. Zeliadt, A.L. Potosky, R. Etzioni, S.D. Ramsey, and D.F. Penson Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999 Urology 64 2004 1171 1176
33. B.A. Mahal, A.A. Aizer, D.R. Ziehr, and et al. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups Urology 84 2014 386 392
34. T. Gilligan, P.S. Wang, R. Levin, P.W. Kantoff, and J. Avorn Racial differences in screening for prostate cancer in the elderly Arch Intern Med 164 2004 1858 1864
35. B.E. Harmon, M.A. Little, E.D. Woekel, and et al. Ethnic differences and predictors of colonoscopy, prostate-specific antigen, and mammography screening participation in the multiethnic cohort Cancer Epidemiol 38 2014 162 167
36. D.F. Ziehr, B.A. Mahal, A.A. Aizer, and et al. Income inequality and treatment of African American men with high-risk prostate cancer Urol Oncol 33 2015 18.e7 18.e13
37. P.B. Bach, D. Schrag, O.W. Brawley, A. Galaznik, S. Yakren, and C.B. Begg Survival of blacks and whites after a cancer diagnosis JAMA 287 2002 2106 2113
38. J.H. Stewart, A.G. Bertoni, J.L. Staten, E.A. Levine, and C.P. Gross Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities Ann Surg Oncol 14 2007 3328 3334
39. V.H. Murthy, H.M. Krumholz, and C.P. Gross Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2004 2720 2726
40. M.D. Wissing, P.G. Kluetz, Y.M. Ning, and et al. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013 Cancer 120 2014 3025 3032
41. F.J. Kim, P.N. Werahera, D.E. Sehrt, D. Gustafson, R.D. Silva, and W.R. Molina Ethnic minorities (African American and Hispanic) males prefer prostate cryoablation as aggressive treatment of localized prostate cancer Can J Urol 21 2014 7305 7311
42. K.A. Moses, A.T. Paciorek, D.F. Penson, P.R. Carroll, and V.A. Master Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE J Clin Oncol 28 2010 1069 1074
43. Q.D. Trinh, J. Schmitges, M. Sun, and et al. Improvement in racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States Cancer 118 2012 1894 1900
44. C.J. Ryan, M.R. Smith, J.S. de Bono, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
45. J.S. de Bono, C.J. Logothetis, A. Molina, and et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
46. I.F. Tannock, K. Fizazi, S. Ivanov, and et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind, randomised trial Lancet Oncol 14 2013 760 768
47. D.I. Quinn, C.M. Tangen, M. Hussain, and et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol 14 2013 893 900
48. W.K. Kelly, S. Halabi, M. Carducci, and et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALBG 90401 J Clin Oncol 30 2012 1534 1540
49. J.S. de Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open label trial Lancet 376 2010 1147 1154
50. D.P. Petrylak, C.M. Tangen, M.H. Hussain, and et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
51. I.F. Tannock, R. de Wit, W.R. Berry, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
52. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, and et al. Enzalutamide in metastatic prostate cancer before chemotherapy. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
53. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
54. E.D. Kwon, C.G. Drake, H.I. Scher, and et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed with docetaxel chemotherapy (CA184-043): a multicenter, randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 700 712
55. D.P. Petrylak, N.J. Vogelzang, N. Budnik, and et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial Lancet Oncol 16 2015 417 425
56. F. Saad, K. Fizazi, V. Jinga, and et al. Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial Lancet Oncol 16 2015 338 348
57. K. Fizazi, R. Jones, S. Oudard, and et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5 J Clin Oncol 33 2015 723 731
58. C. Parker, S. Nilsson, D. Heinrich, and et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
59. C.N. Sternberg, D.P. Petrylak, O. Sartor, and et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
60. D.G. McLeod, D. Quinn, J. Cullen, and J.B. Whitmore Sipuleucel-T in African Americans: a subgroup analysis of three phase 3 trials of sipuleucel-T in metastatic castrate resistant prostate cancer J Urol 187 suppl 2012 e338
61. M.S. Chen Jr., P.N. Lara, J.H. Dang, D.A. Paterniti, and K. Kelly Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual Cancer 120 7 suppl 2014 1091 1096
62. PROVENGE (sipuleucel-T) [prescribing information] 2014 Dendreon Pharmaceuticals Inc Seattle, WA
63. R.F. Tutrone, C. Ahaghotu, A.J. Armstrong, and et al. Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): comparison of clinical trial and real-world experience (abstract 272) J Clin Oncol 33 suppl 7 2015
64. J.M. Unger, D.L. Hershman, K.S. Albain, and et al. Patient income level and cancer clinical trial participation J Clin Oncol 31 2013 536 542
65. V.D. Woods, S.B. Montgomery, and R.P. Herring Recruiting black/African American men for research on prostate cancer prevention Cancer 100 2004 1017 1025
66. L.C. Hanson Improving access and quality of care for African Americans with advanced cancer NC Med J 70 2009 155 158
67. A. Baum, J.P. Garofalo, and A.M. Yali Socioeconomic status and current stress. Does stress account for SES effects on health? Ann N Y Acad Sci 896 1999 131 144
68. N. Chun, and M. Park The impact of health insurance mandates on drug innovation: evidence from the United States Eur J Health Econ 14 2013 323 344
69. Committee on Cancer Clinical Trials and the NCI Cooperative Group Program Board on Health Care Services S.J. Nass, H.L. Moses, and J. Mendelsohn A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program 2010 The National Academies Press Washington DC
70. A.S. Advani, B. Atkeson, C.L. Brown, and et al. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study Cancer 97 2003 1499 1506
71. O.L. Owens, D.D. Jackson, T.L. Thomas, D.B. Friedman, and J.R. Hébert African American men's and women's perceptions of clinical trials research: focusing on prostate cancer among a high-risk population in the South J Health Care Poor Underserved 24 2013 1784 1800
72. K.L. Kehl, N.K. Arora, D. Schrag, and et al. Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer J Natl Cancer Inst 106 2014
73. C.G. Wood, S.J. Wei, M.K. Hampshire, P.A. Devine, and J.M. Metz The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment Am J Clin Oncol 29 2006 593 599
74. P.F. Pinsky, M. Ford, E. Gamito, and et al. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial J Natl Med Assoc 100 2008 291 298
75. W. McCaskill-Stevens, M.M. McKinney, C.G. Whitman, and L.M. Minasian Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience J Clin Oncol 23 2005 5247 5254
76. A.T. Langford, K. Resnicow, E.P. Dimond, and et al. Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program Cancer 120 2014 877 884
77. C.E. Jenkinson, R.E. Winder, H.V. Sugg, and et al. Why do GPs exclude patients from participating in research? An exploration of adherence to and divergence from trial criteria Fam Pract 31 2014 364 370
78. L.L. Adams-Campbell, C. Ahaghotu, M. Gaskins, and et al. Enrollment of African Americans onto clinical treatment trials: study design barriers J Clin Oncol 22 2004 730 734
79. L.C. Brewer, S.N. Hayes, M.W. Parker, and et al. African American women's perceptions and attitudes regarding participation in medical research: the MAYO Clinic/The Links, incorporated partnership J Womens Health 23 2014 681 687
80. C.W. Ramers-Verhoeven, F. Perrone, and K. Oliver Exploratory research into cancer patients' attitudes to clinical trials Ecancermedicalscience 8 2014 432
81. V.L. Shavers, C.F. Lynch, and L.F. Burmeister Racial differences in factors that influence the willingness to participate in medical research studies Ann Epidemiol 12 2002 248 256
82. H.A. Pinto, W. McCaskill-Stevens, P. Wolfe, and A.C. Marcus Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative Ann Epidemiol 10 8 suppl 2000 S78 S84
83. V.L. Shavers, C.F. Lynch, and L.F. Burmeister Factors that influence African-Americans' willingness to participate in medical research studies Cancer 91 1 suppl 2001 233 236
84. G.C. Hughes, B. Knight, L. Fraser, and R. Teague Ethical considerations for conducting cancer medical studies: the Tuskegee Study aftermath Online J Health Ethics 2 2005
85. P. Spain, W.R. Carpenter, J.A. Talcott, and et al. Perceived family history risk and symptomatic diagnosis of prostate cancer: the North Carolina Prostate Cancer Outcomes study Cancer 113 2008 2180 2187
86. A.D. Moore, J.B. Hamilton, G.J. Knafl, and et al. The influence of mistrust, racism, religious participation, and access to care on patient satisfaction of African American men: the North Carolina-Louisiana Prostate Cancer Projects J Natl Med Assoc 105 2013 59 68
87. R.F. Brown, D.L. Cadet, R.H. Houlihan, and et al. Perceptions of participation in a phase I, II or III clinical trial among African American patients with cancer: what do refusers say? J Oncol Prac 9 2013 287 293
88. D.M. Mandal, O. Sartor, S.L. Halton, D.E. Mercante, J.E. Bailey-Wilson, and W. Rayford Recruitment strategies and comparison of prostate cancer specific clinical data on African-American and Caucasian males with or without family history Prostate Cancer Prostatic Dis 11 2008 274 279
89. K.R. Evans, M.J. Lewis, and S.V. Hudson The role of health literacy on African American and Hispanic/Latino perspectives on cancer clinical trials J Cancer Educ 27 2012 299 305
90. M.G. Sabir, and K.A. Pillemer An intensely sympathetic awareness: experiential similarity and cultural norms as means of gaining older African Americans' trust of scientific research J Aging Stud 29 2014 142 149
91. C.L. Holt, T.A. Wynn, M.S. Litaker, P. Southward, S. Jeames, and E. Schulz A comparison of a spiritually based and non-spiritually based educational intervention for informed decision making for prostate cancer screening among church-attending African-American men Urol Nurs 29 2009 249 258
92. E.P. Dimond, D. St Germain, L.M. Nacpil, and et al. Creating a "culture of research" in a community hospital: strategies and tools from the National Cancer Institute Community Cancer Centers Program Clin Trials 12 2015 246 256
93. W.R. Carpenter, S. Tyree, Y. Wu, and et al. A surveillance system for monitoring, public reporting, and improving minority access to cancer clinical trials Clin Trials 9 2012 426 435
94. T. Samuel Standardizing a process to engage African Americans in health research: the Community Research Outreach Workers' Network (CROWN) Prog Community Health Partnership 8 2014 109 116
95. M.A. Green, M. Michaels, N. Blakeney, and et al. Evaluating a community-partnered cancer clinical trials pilot intervention with African American communities J Cancer Educ 30 2015 158 166
96. S.P. Heiney, S. Arp Adams, B.F. Drake, L.H. Bryant, L. Bridges, and J.R. Hebert Successful subject recruitment for a prostate cancer behavioral interventional trial Clin Trials 7 2010 411 417
97. M.E. Ford, S.L. Havstad, and S.D. Davis A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Clin Trials 1 2004 343 351
98. R.J. Wray, S. McClure, S. Vijaykumar, and et al. Changing the conversation about prostate cancer among African Americans: results of formative research Ethn Health 14 2009 27 43
99. S.P. Weinrich, M.D. Boyd, M. Weinrich, F. Greene, W.A. Reynolds Jr., and C. Metlin Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions J Cancer Educ 13 1998 213 219
100. R.A. Jones, R. Steeves, and I. Williams Strategies for recruiting African American men into prostate cancer screening studies Nurs Res 58 2009 452 456
101. P.M. Fracasso, S.A. Goodner, A.N. Creekmore, and et al. Coaching intervention as a strategy for minority recruitment to cancer clinical trials J Oncol Prac 9 2013 294 299
102. K.E. Lasser, J. Murillo, S. Lisboa, and et al. Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial Arch Intern Med 171 2011 906 912
103. F.L. Stallings, M.E. Ford, N.K. Simpson, and et al. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Control Clin Trials 21 6 suppl 2000 379S 389S
104. S.M. Miller, P. Roussi, J. Scarpato, K.Y. Wen, F. Zhu, and G. Roy Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men Psychooncology 23 2014 404 411
105. S.D. Brown, K. Lee, D.E. Schoffman, A.C. King, L.M. Crawley, and M. Kiernan Minority recruitment into clinical trials: experimental findings and practical implications Contemp Clin Trials 33 2012 620 623
106. B.A. Husaini, M.C. Reece, J.S. Emerson, S. Scales, P.C. Hull, and R.S. Levine A church-based program on prostate cancer screening for African American men: reducing health disparities Ethn Dis 18 2 suppl 2 2008 179 184
107. Ashrorobi OS, Frost J, Wang X, et al. Prostate cancer education, detection, and follow-up in a community-based multiethnic cohort of medically underserved men. Am J Mens Health, Published online May 18, 2015.
108. A.T. Langford, D.M. Griffith, D.D. Beasley, and E.I. Braxton A cancer center's approach to engaging African American men about cancer: the Men's Fellowship Breakfast, Southeastern Michigan, 2008-2014 Prev Chronic Dis 11 2014 140187
109. B.F. Drake, R.C. Shelton, T. Gilligan, and J.D. Allen A church-based intervention to promote informed decision making for prostate cancer screening among African American men J Natl Med Assoc 102 2010 164 171
110. G. Corbie-Smith, S. Moody-Ayers, and A.D. Thrasher Closing the circle between minority inclusion in research and health disparities Arch Intern Med 164 2004 1362 1364
111. N.K. Simpson, C.C. Johnson, S.L. Ogden, and et al. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years Control Clin Trials 21 6 suppl 2000 356S 378S
112. D. Dohan, and D. Schrag Using navigators to improve care of underserved patients: current practices and approaches Cancer 104 2005 848 855
113. FDA Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM334959.pdf 2011 Accessed: August 20, 2015
114. C. Royal, A. Baffoe-Bonni, R. Kittles, and et al. Recruitment experience in the first phase of the African American Heredity Prostate Cancer (AAHPC) study Ann Epidemiol 10 8 suppl 2000 S68 S77
115. C. Ahaghotu, A. Baffoe-Bonnie, R. Kittles, and et al. Clinical characteristics of African-American men with hereditary prostate cancer Prostate Cancer Prostatic Dis 7 2004 165 169
116. V.D. Woods, S.B. Montgomery, J.C. Belliard, J. Ramirez-Johnson, and C.M. Wilson Culture, black men, and prostate cancer: what is reality? Cancer Control 11 2004 388 396
117. C. Hughes Halbert, B. Weathers, and E. Delmoor Developing an academic-community partnership for research in prostate cancer J Cancer Educ 21 2006 99 103
118. S.A. Adams, S.P. Heiney, H.M. Brandt, and et al. A comparison of a centralized versus de-centralized recruitment schema in two-community based participatory research studies for cancer prevention J Community Health 40 2015 251 259
119. E.D. Cook, S. Moody-Thomas, K.B. Anderson, and et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) Clin Trials 2 2005 436 442
120. T.J. Daskivich, L. Kwan, A. Dash, and M.S. Litwin Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system Prostate Cancer Prostatic Dis 18 2015 104 109